HPLC SEPARATION AND DETERMINATION OF ZIPRASIDONE

Ewa Chojecka-Koryn ,  Katarzyna Korczak ,  Magdalena M. Glice ,  Katarzyna Badowska-Rosłonek ,  Roman Balicki 

Pharmaceutical Research Institute (IF), Rydygiera 8, Warszawa 01-793, Poland

Abstract

Ziprasidone (5-(2-(4-(1,2-benzisothiazol-3-yl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one hydrochloride monohydrate (3)) with the chemical formula C21H21ClN4OS* HCl*H2O) is a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Clinical trials suggest that the drug is an effective antipsychotic in schizophrenia and schizoaffective disorder with a beneficial effect on negative symptoms and symptoms of depression.

The monohydrate hydrochloride (3) was obtained from the appropriate base prepared in condensation reaction of starting materials 1 and 2. For the final product purity determination a simple analytical method was developed.

High-Performance Liquid Chromatography (HPLC) is a simple analytical technique for the separation and determination of organic analytes in pharmaceutical samples.

The optimalization of the reversed phase high-performance liquid chromatographic separation of ziprasidone and starting materials is described. This method was successfully applied to the analysis of compound purity. The method is sufficiently simple and rapid for the quality assurance of this type of compounds. The peaks in the chromatograms of a mixture were identified based on the retention times of isolated components injected separately.

The X-Ray powder diffraction method (XRPD) and infrared spectroscopy (IR) were used to identify and characterize the samples of substance and tablets of Ziprasidone toward the polymorphic form.

 

Related papers
  1. Hplc study of Cilostazol tablets: assay and release profile determination
  2. Validation of HPLC methods for analyzing the chemical purity of cilostazol
  3. Identification of degradation products of cilostazol drug substance
  4. HPLC methods for in–process control and chemical purity determination of olopatadine
  5. Analytical control of synthesis and determination of BR-S by HPLC
  6. Optimization of BR-8 synthesis
  7. HPLC Methods for Stress Testing of ZL-S Drug Substances
  8. Problems of determination of selected Class 1 residual solvents (according to ICH*)) as process impurities of some Class 3 and 2 solvents in API by GC-HS method
  9. Structural characterization of PX-S
  10. Zolmitriptan synthesis and in-process control by HPLC methods
  11. The cytotoxic activity of glycosides of indolo[2,3-b]quinoline derivatives.
  12. The Crystal Structure of distrontium salt of 5-[bis(carboxymethyl)amino]-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid
  13. Development of HPLC and GC methods for analysis of Zolmitriptan of pharmaceutical purity
  14. Optimization of AR-3 synthesis
  15. QUINONES AND HYDROQUINONES SEPARATION AND DETERMINATION BY HPLC CHROMATOGRAPHY
  16. CHARACTERIZATION OF ARIPIPRAZOLE SOLVATE WITH ETHANOL AND POLYMORPHIC FORMS PRODUCED DURING ITS HEATING
  17. SYNTHESIS OF GLIMEPIRIDE - CRYSTAL STRUCTURE ANALYSIS STEP BY STEP
  18. HPLC AS A METHOD FOR ANALYTICAL CONTROL OF SYNTHESIS AND DETERMINATION OF PRAMIPEXOLE
  19. THE CYTOTOXIC GLYCOSIDES OF INDOLO[2,3-B]QUINOLINE DERIVATIVES. IN VITRO AND IN VIVO STUDIES
  20. A NEW, EFFICIENT AND ECONOMIC METHOD FOR PREPARATION OF PRAMIPEXOLE.
  21. 1H AND 13C NMR DATA FOR INDOLO[2,3-b]QUINOLINES - AMINOGLYCOSIDE HYBRIDS, A NOVEL POTENT ANTICANCER DRUG FAMILY .
  22. NEW SYNTHESIS OF 11-(1-PIPERAZINYL)- DIBENZO[b,f][1,4]THIAZEPINE, A CRUCIAL INTERMEDIATE IN QUETIAPINE PRODUCTION.

Presentation: Poster at V Multidyscyplinarna Konferencja Nauki o Leku, by Ewa Chojecka-Koryn
See On-line Journal of V Multidyscyplinarna Konferencja Nauki o Leku

Submitted: 2006-03-06 10:08
Revised:   2009-06-07 00:44